S&P 500 7,650.50 0.17% Nasdaq 26,522.55 0.39% Dow Jones 51,682.64 0.18% Russell 2000 2,860.40 0.50% Gold 4,424.90 0.57% Bitcoin-USD 81,229.51 0.44% AAPL 336.13 0.26% MSFT 493.78 0.80% GOOGL 349.54 0.64% AMZN 253.71 1.00% NVDA 222.27 1.34% META 665.75 2.43% TSLA 364.27 0.53%

NASDAQ : ABVX

ABVX logoAbivax S.A. (ABVX)Healthcare : Biotechnology
You need sign in

$105,04

-1.95 (-1.82%) today

After-hours $105,01 -1.98 (-1.85%)
Overview News Earnings Leadership

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

CEO:
Marc de Garidel
Country:
FR
Full-time employees:
80
Address:
7-11 Boulevard Haussmann, Paris, IF, 75009
IPO date:
Oct 20, 2023

Open

$106,84

High

$106,84

Low

$103,90

Mkt. cap

7.71B

Avg. vol.

1.75M

Volume

870.89K

52-wk high

$148,83

52-wk low

$69,81

Shares outstanding

73.43M